KR20240022646A - 화합물, 엔도텔린 a 수용체 길항제 및 의약 조성물 - Google Patents

화합물, 엔도텔린 a 수용체 길항제 및 의약 조성물 Download PDF

Info

Publication number
KR20240022646A
KR20240022646A KR1020247002106A KR20247002106A KR20240022646A KR 20240022646 A KR20240022646 A KR 20240022646A KR 1020247002106 A KR1020247002106 A KR 1020247002106A KR 20247002106 A KR20247002106 A KR 20247002106A KR 20240022646 A KR20240022646 A KR 20240022646A
Authority
KR
South Korea
Prior art keywords
mmol
added
mixture
reaction mixture
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247002106A
Other languages
English (en)
Korean (ko)
Inventor
게이고 다나카
도모히사 니노미야
요시히데 도마타
Original Assignee
앨커메디신, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앨커메디신, 인크. filed Critical 앨커메디신, 인크.
Publication of KR20240022646A publication Critical patent/KR20240022646A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020247002106A 2021-06-22 2022-06-21 화합물, 엔도텔린 a 수용체 길항제 및 의약 조성물 Pending KR20240022646A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2021-103047 2021-06-22
JP2021103047 2021-06-22
PCT/JP2022/024638 WO2022270487A1 (ja) 2021-06-22 2022-06-21 化合物、エンドセリンａ受容体拮抗剤及び医薬組成物

Publications (1)

Publication Number Publication Date
KR20240022646A true KR20240022646A (ko) 2024-02-20

Family

ID=84545734

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247002106A Pending KR20240022646A (ko) 2021-06-22 2022-06-21 화합물, 엔도텔린 a 수용체 길항제 및 의약 조성물

Country Status (12)

Country Link
US (1) US20240287053A1 (https=)
EP (1) EP4361146A4 (https=)
JP (1) JP7531947B2 (https=)
KR (1) KR20240022646A (https=)
CN (1) CN117255791A (https=)
AR (1) AR126178A1 (https=)
AU (1) AU2022297082B2 (https=)
BR (1) BR112023019460A2 (https=)
CA (1) CA3217189A1 (https=)
IL (1) IL306095A (https=)
MX (1) MX2023014455A (https=)
WO (1) WO2022270487A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
WO1996031492A1 (en) 1995-04-04 1996-10-10 Texas Biotechnology Corporation Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
WO1996040681A1 (en) 1995-06-07 1996-12-19 Zeneca Limited N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
WO1998013366A1 (en) 1996-09-27 1998-04-02 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
WO1998033780A1 (en) 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Endothelin antagonists: n-[[2'-[ [(4,5-dimethyl-3-isoxazolyl) amino]sulfonyl]-4-(2-oxazolyl) [1,1'-biphenyl]-2-yl]methyl] -n,3,3-trimethylbutanamide and n-(4,5-dimethyl-3-isoxazolyl) -2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl) methyl] -4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfonamide and salts thereof
WO1998033781A1 (en) 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
WO1998049162A1 (en) 1997-04-28 1998-11-05 Texas Biotechnology Corporation Sulfonamides for treatment of endothelin-mediated disorders
WO2001049685A2 (en) 1999-12-31 2001-07-12 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
WO2004035057A1 (en) 2002-10-12 2004-04-29 Astrazeneca Ab Therapeutic treatment
WO2013115162A1 (ja) 2012-01-31 2013-08-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 シタキセンタン誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US8859541B2 (en) * 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
WO1996031492A1 (en) 1995-04-04 1996-10-10 Texas Biotechnology Corporation Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
WO1996040681A1 (en) 1995-06-07 1996-12-19 Zeneca Limited N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
WO1998013366A1 (en) 1996-09-27 1998-04-02 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
WO1998033780A1 (en) 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Endothelin antagonists: n-[[2'-[ [(4,5-dimethyl-3-isoxazolyl) amino]sulfonyl]-4-(2-oxazolyl) [1,1'-biphenyl]-2-yl]methyl] -n,3,3-trimethylbutanamide and n-(4,5-dimethyl-3-isoxazolyl) -2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl) methyl] -4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfonamide and salts thereof
WO1998033781A1 (en) 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
WO1998049162A1 (en) 1997-04-28 1998-11-05 Texas Biotechnology Corporation Sulfonamides for treatment of endothelin-mediated disorders
WO2001049685A2 (en) 1999-12-31 2001-07-12 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
WO2004035057A1 (en) 2002-10-12 2004-04-29 Astrazeneca Ab Therapeutic treatment
WO2013115162A1 (ja) 2012-01-31 2013-08-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 シタキセンタン誘導体

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
비특허문헌 1: The New England Journal of Medicine, 2002, 346, pp 896-903.
비특허문헌 10: Drug Research, 2015, 65, pp 272-280.
비특허문헌 11: World Journal of Hepatology, 2016, 8, pp 933-941.
비특허문헌 12: Digestive Diseases and Sciences, 2007, 52, pp 2622-2628.
비특허문헌 13: Nature reviews cancer, 2013, 13, pp 637-651.
비특허문헌 14: European Journal of Pain, 2018, 22, pp 501-510.
비특허문헌 15: Fertility and Sterility, 1994, 61, pp 1083- 1087.
비특허문헌 16: Inflammation & Allergy-Drug Targets, 2011, 10, pp 19-26.
비특허문헌 17: Annals of the Rheumatic Diseases, 2011, 70, pp 32-38.
비특허문헌 18: Molecular medicine reports, 2018, 18, pp 5229-5236.
비특허문헌 19: Journal of the American Heart Association, 2014, 3, e001263.
비특허문헌 2: International Heart Journal, 2020, 61, pp 799-805.
비특허문헌 20: European Heart Journal, 2008, 29, pp 1936-1948.
비특허문헌 21: Pharmacological Reviews, 2016, 68, pp. 357-418.
비특허문헌 22: Annual Review of Pharmacology and Toxicology, 2007, 47, pp 731-759.
비특허문헌 3: Journal of the American society of Nephrology, 2018, 29, pp 2745-2754.
비특허문헌 4: Nephron, 1996, 72, pp 454-460.
비특허문헌 5: The Lancet, 2019, 393, pp 1937-1947.
비특허문헌 6: Hypertension, 2011, 57, pp 772-779.
비특허문헌 7: Journal of the American society of Nephrology, 2017, 28, pp 2443-2458.
비특허문헌 8: Transplantation, 2001, 71, pp 211-216.
비특허문헌 9: Hypertension, 2008, 52, pp 452-459.

Also Published As

Publication number Publication date
IL306095A (en) 2023-11-01
JP7531947B2 (ja) 2024-08-13
US20240287053A1 (en) 2024-08-29
CA3217189A1 (en) 2022-12-29
CN117255791A (zh) 2023-12-19
TW202317555A (zh) 2023-05-01
BR112023019460A2 (pt) 2024-01-23
JPWO2022270487A1 (https=) 2022-12-29
AU2022297082A1 (en) 2023-09-28
WO2022270487A1 (ja) 2022-12-29
AR126178A1 (es) 2023-09-27
EP4361146A4 (en) 2025-06-18
EP4361146A1 (en) 2024-05-01
AU2022297082B2 (en) 2024-04-18
MX2023014455A (es) 2023-12-15

Similar Documents

Publication Publication Date Title
JP6409004B2 (ja) ソルチリン阻害剤としてのｎ置換された５置換フタルアミド酸
CA2830742C (en) Substituted oxanes as opioid receptor ligands and methods of using and making same
PT1354884E (pt) Composto de ciclopenta (d) pirazolo [1,5-a] piramida como antagonista de receptor de crf
CA2693552A1 (en) Pyridone compound
CN105073725A (zh) 作为激酶抑制剂的吡唑基-脲
BR112016003247B1 (pt) Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso
JP6670906B2 (ja) 新しい３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物
JP2021512114A (ja) 窒素含有三環式化合物及び医薬品におけるその使用
CN106132945B (zh) 酰胺化合物
CN105102450A (zh) 作为PERK抑制剂的新颖的N-(2，3-二氢-1H-吡咯并[2，3-b]吡啶-5-基)-4-喹唑啉胺和N-(2，3-二氢-1H-吲哚-5-基)-4-喹唑啉胺衍生物
EP4003991A1 (en) Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
ES2308296T3 (es) Modulares del receptor nuclear de hormonas esteroideas triciclicas.
KR20240022646A (ko) 화합물, 엔도텔린 a 수용체 길항제 및 의약 조성물
CN111303147B (zh) 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CN105026392A (zh) 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮衍生物、其制备方法以及应用
KR102193247B1 (ko) 헤테로 고리 아세트산아미드 화합물
RU2681316C2 (ru) Производные циклогексилпиридина
RU2831561C2 (ru) Соединение, антагонист эндотелинового рецептора a и фармацевтическая композиция
CN115353508A (zh) 5-吡啶-1h-吲唑类化合物、药物组合物和应用
TWI918959B (zh) 化合物、內皮素a受體拮抗劑及醫藥組合物
CN121773091A (zh) 杂芳环衍生物的lpar1拮抗剂及其用途
CN121866249A (zh) 一种lpar1拮抗剂及其用途
WO2022007168A1 (zh) 一种苯并五元氮杂环化合物及其应用
HK40108888A (en) Compound, endothelin-a receptor antagonist, and pharmaceutical composition
JP2017525734A (ja) 癌の治療において有用なイソキノリノン誘導体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000